Pityriasis rubra pilaris induced by PD-1 inhibitor nivolumab

Int J Dermatol. 2021 Aug;60(8):1038-1039. doi: 10.1111/ijd.15563. Epub 2021 Apr 12.

Authors

Tal Goldberger^{1

2}, Gil Armoni^{1

2}, David Lavie^{1

3}, Sharon Merims^{1

4}, Alexander Maly^{1

5}, Rony Shreberk-Hassidim^{1

2}

Affiliations

¹ The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
² Department of Dermatology, Hadassah Medical Center, Jerusalem, Israel.
³ Department of Hematology, Hadassah Medical Center, Jerusalem, Israel.
⁴ Department of Oncology, Hadassah Medical Center, Jerusalem, Israel.
⁵ Department of Pathology, Hadassah Medical Center, Jerusalem, Israel.

PMID: 33846975
DOI: 10.1111/ijd.15563

No abstract available

Publication types

Letter

MeSH terms

Humans
Immune Checkpoint Inhibitors
Nivolumab* / adverse effects
Pityriasis Rubra Pilaris* / chemically induced
Pityriasis Rubra Pilaris* / drug therapy

Substances

Immune Checkpoint Inhibitors
Nivolumab